We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 20, 2021

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting

JACC: Cardiovascular Interventions

 

Additional Info

JACC: Cardiovascular Interventions
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial
JACC Cardiovasc Interv 2021 Nov 08;14(21)2330-2340, T Matoba, S Yasuda, K Kaikita, M Akao, J Ako, M Nakamura, K Miyauchi, N Hagiwara, K Kimura, A Hirayama, K Matsui, H Ogawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading